Nicole Onetto

TL;DR: It is found that frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, are also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement ofAxon guidance genes in pancreatic carcinogenesis.

TL;DR: The timing is right to develop a clinical trial and research framework to move future clinical decisions from heuristic to evidence-based decisions, and the challenges of integrating genomic testing into cancer treatment decision making are wide-ranging and complex.

TL;DR: The technology underlying cancer genomics is highlighted and the early results of genome sequencing and the challenges met in the discovery of new genetic aberrations are examined.

TL;DR: It is demonstrated that the use of next generation sequencing for real‐time genomic profiling in advanced cancer patients is feasible and actionable mutations identified in this study were relatively stable between archival and biopsy samples, implying that cancer mutations that are good predictors of drug response may remain constant across clinical stages.